241 related articles for article (PubMed ID: 23425521)
1. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Agewall S; Cattaneo M; Collet JP; Andreotti F; Lip GY; Verheugt FW; Huber K; Grove EL; Morais J; Husted S; Wassmann S; Rosano G; Atar D; Pathak A; Kjeldsen K; Storey RF;
Eur Heart J; 2013 Jun; 34(23):1708-13, 1713a-1713b. PubMed ID: 23425521
[No Abstract] [Full Text] [Related]
2. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Floyd CN; Passacquale G; Ferro A
Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
[TBL] [Abstract][Full Text] [Related]
3. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Scharbert G; Wetzel L; Schrottmaier WC; Kral JB; Weber T; Assinger A
Transfusion; 2015 Jun; 55(6):1320-6. PubMed ID: 25641006
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
Kirkby NS; Leadbeater PD; Chan MV; Nylander S; Mitchell JA; Warner TD
J Thromb Haemost; 2011 Oct; 9(10):2103-5. PubMed ID: 21812912
[No Abstract] [Full Text] [Related]
5. [Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Gratsianskiĭ NA
Kardiologiia; 2010; 50(6):4-21. PubMed ID: 20659022
[TBL] [Abstract][Full Text] [Related]
6. [Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions].
Würtz M; Grove EL
Ugeskr Laeger; 2013 Sep; 175(37):2094-8. PubMed ID: 24011204
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Wijeyeratne YD; Joshi R; Heptinstall S
Expert Rev Clin Pharmacol; 2012 May; 5(3):257-69. PubMed ID: 22697589
[TBL] [Abstract][Full Text] [Related]
8. [Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Stiefelhagen P
MMW Fortschr Med; 2013 Feb; 155(3):18. PubMed ID: 23573760
[No Abstract] [Full Text] [Related]
9. Resistance to anti-platelet agents.
Cattaneo M
Thromb Res; 2011 Feb; 127 Suppl 3():S61-3. PubMed ID: 21262444
[TBL] [Abstract][Full Text] [Related]
10. [Myocardial infarction: Role of new antiplatelet agents].
Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
[TBL] [Abstract][Full Text] [Related]
11. The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Cattaneo M
Blood; 2011 Feb; 117(7):2102-12. PubMed ID: 20966167
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.
Grzesk G; Kozinski M; Navarese EP; Krzyzanowski M; Grzesk E; Kubica A; Siller-Matula JM; Castriota F; Kubica J
Thromb Res; 2012 Jul; 130(1):65-9. PubMed ID: 22265722
[TBL] [Abstract][Full Text] [Related]
14. Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus.
Storey RF; Parker WA
Circulation; 2016 Sep; 134(11):793-6. PubMed ID: 27619715
[No Abstract] [Full Text] [Related]
15. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.
Ancrenaz V; Daali Y; Fontana P; Besson M; Samer C; Dayer P; Desmeules J
Curr Drug Metab; 2010 Oct; 11(8):667-77. PubMed ID: 20942779
[TBL] [Abstract][Full Text] [Related]
16. [New antithrombotic drugs].
Mustonen P; Puurunen M
Duodecim; 2012; 128(7):707-18. PubMed ID: 22612021
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
18. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
Clemmensen P; Dridi NP; Holmvang L
Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
[TBL] [Abstract][Full Text] [Related]
19. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.
Abraham NS; Hlatky MA; Antman EM; Bhatt DL; Bjorkman DJ; Clark CB; Furberg CD; Johnson DA; Kahi CJ; Laine L; Mahaffey KW; Quigley EM; Scheiman J; Sperling LS; Tomaselli GF;
Am J Gastroenterol; 2010 Dec; 105(12):2533-49. PubMed ID: 21131924
[No Abstract] [Full Text] [Related]
20. Advances in the monitoring of anti-P2Y12 therapy.
Harrison P
Platelets; 2012; 23(7):510-25. PubMed ID: 22916724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
